Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Background: At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to d...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repositorio: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p5319 |
| Acceso en línea: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5319 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123687363&doi=10.21037%2ftlcr-21-504&partnerID=40&md5=eb88f627c270d009fdd89b6be6314158 |
| Access Level: | acceso abierto |
| Palabra clave: | Immunity lung cancer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence |
| id |
ES_8b08ba34e68f10ebcef9dbf453c703d2 |
|---|---|
| oai_identifier_str |
oai:iibsantpau.fundanetsuite.com:p5319 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID studyProvencio, MRodriguez-Abreu, DOrtega, ALSerrano, GAguado, CFranco, FGutierrez, VVivanco, GLGuirado, MBenitez, GEstival, ACalvo, VJimenez, BArasanz, HCoves, JMajem, MMassuti, BVazquez, SJuan-Vidal, OCollazo-Lorduy, AGozalvez, CLDel Barco, ERosero, ABosch-Barrerra, JMoreno, MAMielgo-Rubio, XVilla, JCLopez-Martin, ACordoba, JFAparisi, FDZafra, MMosquera, JAltozano, JPNadal, ECatot, SBalsalobre, JDe Portugal, TMartin, PDe Juan, SCCobo, MImmunitylung cancersevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)seroprevalenceBackground: At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. Methods: This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using ELISA kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARSCoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Results: Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Conclusions: Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. Trial Registration: ClinicalTrials.gov identifier: NCT04407143.AME PUBL CO2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5319https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123687363&doi=10.21037%2ftlcr-21-504&partnerID=40&md5=eb88f627c270d009fdd89b6be6314158Translational Lung Cancer ResearchISSN: 22186751ISSNe: 22264477reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p53192026-06-14T12:41:47Z |
| dc.title.none.fl_str_mv |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| title |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| spellingShingle |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study Provencio, M Immunity lung cancer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence |
| title_short |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| title_full |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| title_fullStr |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| title_full_unstemmed |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| title_sort |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study |
| dc.creator.none.fl_str_mv |
Provencio, M Rodriguez-Abreu, D Ortega, AL Serrano, G Aguado, C Franco, F Gutierrez, V Vivanco, GL Guirado, M Benitez, G Estival, A Calvo, V Jimenez, B Arasanz, H Coves, J Majem, M Massuti, B Vazquez, S Juan-Vidal, O Collazo-Lorduy, A Gozalvez, CL Del Barco, E Rosero, A Bosch-Barrerra, J Moreno, MA Mielgo-Rubio, X Villa, JC Lopez-Martin, A Cordoba, JF Aparisi, FD Zafra, M Mosquera, J Altozano, JP Nadal, E Catot, S Balsalobre, J De Portugal, T Martin, P De Juan, SC Cobo, M |
| author |
Provencio, M |
| author_facet |
Provencio, M Rodriguez-Abreu, D Ortega, AL Serrano, G Aguado, C Franco, F Gutierrez, V Vivanco, GL Guirado, M Benitez, G Estival, A Calvo, V Jimenez, B Arasanz, H Coves, J Majem, M Massuti, B Vazquez, S Juan-Vidal, O Collazo-Lorduy, A Gozalvez, CL Del Barco, E Rosero, A Bosch-Barrerra, J Moreno, MA Mielgo-Rubio, X Villa, JC Lopez-Martin, A Cordoba, JF Aparisi, FD Zafra, M Mosquera, J Altozano, JP Nadal, E Catot, S Balsalobre, J De Portugal, T Martin, P De Juan, SC Cobo, M |
| author_role |
author |
| author2 |
Rodriguez-Abreu, D Ortega, AL Serrano, G Aguado, C Franco, F Gutierrez, V Vivanco, GL Guirado, M Benitez, G Estival, A Calvo, V Jimenez, B Arasanz, H Coves, J Majem, M Massuti, B Vazquez, S Juan-Vidal, O Collazo-Lorduy, A Gozalvez, CL Del Barco, E Rosero, A Bosch-Barrerra, J Moreno, MA Mielgo-Rubio, X Villa, JC Lopez-Martin, A Cordoba, JF Aparisi, FD Zafra, M Mosquera, J Altozano, JP Nadal, E Catot, S Balsalobre, J De Portugal, T Martin, P De Juan, SC Cobo, M |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Immunity lung cancer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence |
| topic |
Immunity lung cancer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence |
| description |
Background: At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. Methods: This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using ELISA kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARSCoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Results: Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Conclusions: Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. Trial Registration: ClinicalTrials.gov identifier: NCT04407143. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5319 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123687363&doi=10.21037%2ftlcr-21-504&partnerID=40&md5=eb88f627c270d009fdd89b6be6314158 |
| url |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5319 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123687363&doi=10.21037%2ftlcr-21-504&partnerID=40&md5=eb88f627c270d009fdd89b6be6314158 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
AME PUBL CO |
| publisher.none.fl_str_mv |
AME PUBL CO |
| dc.source.none.fl_str_mv |
Translational Lung Cancer Research ISSN: 22186751 ISSNe: 22264477 reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| instname_str |
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| reponame_str |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| collection |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869412777751216128 |
| score |
15.812429 |